Drug Trial Radar · NCT00269412
Study to Assess the Efficacy and Safety of Rifaximin Administered BID in the Treatment of Patients With Diarrhea-Associated Irritable Bowel Syndrome
Last checked: Nov 20, 2026Latest source record: Nov 25, 2019 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
525
Planned (sponsor's estimate)
Start
Dec 2005
Primary completion
Aug 2007
Study completion Sep 2008
Sponsor
- Lead sponsor
- Bausch Health Americas, Inc.Industry
- Sponsor type
- Industry
- First posted
- Dec 23, 2005
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is placebo-controlled study of three rifaximin doses in patients with DIBS. Subjects will be randomized to receive daily doses of placebo BID, rifaximin 275 mg BID, rifaximin 550 mg BID, or 1100 mg BID for 14 days. These four groups will subsequently receive an additional two weeks of placebo for a total of 4 weeks of treatment. A fifth group of subjects will receive rifaximin 550 mg BID for a period of 28 days. Subjects who successfully respond to treatment at the end of the 28-day Treatment Phase will be followed in a Post-treatment Phase that includes study visits during Weeks 6, 8, 12 and 16. Subjects who relapse during the Post-treatment Phase will be discontinued from the study.
Conditions
- Irritable Bowel Syndrome
Interventions
RifaximinDrug
Primary outcomes
What the sponsor says the trial is designed to measure.
- The primary objective of this trial is to evaluate the efficacy of a 14-day course of oral rifaximin at 550 mg BID versus placebo in providing adequate relief from Diarrhea-associated IBS (DIBS) symptoms.
Locations
67 sites in 1 country. Site status is shown where the registry gives one.
Mayo Clinic Scottsdale
Scottsdale, Arizona
Premeire Pharmaceutical Research
Tempe, Arizona
Advanced Clinical Research Institute
Anaheim, California
Lovelace Scientific Resources
Irvine, California
West Gastroenterology Medical Group
Los Angeles, California
Beverly Hills Gastroenterology
Los Angeles, California
Medical Associates Research Group
San Diego, California
Gastroenterology Associates of Fairfield County
Bridgeport, Connecticut
Connecticut Gastroenterology Institute
Bristol, Connecticut
Litchfield County Gastroenterology Associates, LLC
Torrington, Connecticut
Clinical Research of West Florida
Clearwater, Florida
University Clinical Research
DeLand, Florida
Research Consultants Group
Hialeah, Florida
Borland-Groover Clinic
Jacksonville, Florida
Miami Research Associates
Miami, Florida
Advanced Gastroenterology Associates
Palm Harbor, Florida
Shafran Gastroenterology
Winter Park, Florida
Florida Medical Clinic
Zephyrhills, Florida
Rockford Gastroenterology
Rockford, Illinois
Community Clinical Research Center
Anderson, Indiana
Indianapolis Gastroenterology Research Foundation
Indianapolis, Indiana
Gastrointestinal Clinic of Quad Citites
Davenport, Iowa
University of Kansas Medical Center
Kansas City, Kansas
Digestive Disorders Associates
Annapolis, Maryland
Chevy Chase Clinical Research
Chevy Chase, Maryland
Washington County Hospital
Hagerstown, Maryland
Maryland Clinical Trials
Severna Park, Maryland
Capital Gastroenterology Consultants, PA
Silver Springs, Maryland
Coastal Research Associates
Braintree, Massachusetts
Henry Ford Hospital
Chesterfield, Michigan
Gastrointestinal Associates, PA
Jackson, Mississippi
Digestive Health Specialists, PA
Tupelo, Mississippi
Gastroenterology and Hepatology
Kansas City, Missouri
Center for Digestive & Liver Diseases, Inc.
Mexico, Missouri
Specialist in Gastroenterology
St Louis, Missouri
Gastroenterology Specialities
Lincoln, Nebraska
Long Island Clinical Research
Great Neck, New York
New York Center for Clinical Research
Lake Success, New York
Asheville Gastroenterology Associates
Asheville, North Carolina
University of North Carolina
Chapel Hill, North Carolina
Showing 40 of 67 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.